What is the appropriate starting dose, titration schedule, monitoring, and precautions for tizanidine in a patient with spasticity?

Tizanidine for Spasticity Management

Start tizanidine at 2-4 mg orally at bedtime, increase by 2-4 mg every 3-7 days as tolerated to a maximum of 36 mg/day in divided doses (every 6-8 hours), with most patients achieving benefit at 24-36 mg/day. 1

Starting Dose and Titration

Begin with 2-4 mg orally at bedtime to minimize initial sedation and assess tolerability 2, 1. The single-dose approach allows you to evaluate the patient's response to the medication's peak effect at 1-2 hours and duration of 3-6 hours 1.

Titration Schedule:

• Increase by 2-4 mg increments every 3-7 days based on tolerability 1, 3
• Dose can be repeated every 6-8 hours as needed, up to 3 doses per 24 hours 1
• Maximum daily dose: 36 mg/day (though most clinical experience is with ≤24 mg/day) 1
• Effective dose range: 24-36 mg/day in divided doses for most patients 4, 5

The titration period typically takes 2-4 weeks to reach optimal dosing 3, 6. Only 21% of patients in clinical trials reached the maximum 36 mg/day dose, indicating most achieve adequate spasticity control at lower doses 7.

Clinical Efficacy by Condition

Tizanidine demonstrates particular efficacy in chronic stroke patients (>6 months post-stroke) with improvement in spasticity and pain without loss of motor strength 8, 7. The 2005 Stroke Rehabilitation Guidelines specifically recommend tizanidine for chronic stroke patients 8.

Evidence also supports use in:

• Multiple sclerosis (20% mean reduction in muscle tone at 24-36 mg/day) 4
• Spinal cord injury (significant Ashworth score reduction) 9
• Acquired brain injury 6, 5

Critical Drug Interactions and Contraindications

Absolute Contraindications:

• Concomitant use with ciprofloxacin or fluvoxamine (contraindicated due to severe reduction in tizanidine clearance) 10

Relative Contraindications/Cautions:

• Hepatic or renal dysfunction - avoid or use with extreme caution 10
• Elderly patients - increased risk of sedation and hypotension 10
• CYP1A2 inhibitors (oral contraceptives, acyclovir, amiodarone, verapamil, mexiletine, propafenone, cimetidine, famotidine) - can cause significant hypotension, bradycardia, and sedation 10
• Concomitant methadone use - increased risk of QTc prolongation 2

Monitoring Requirements

Before Initiating:

• Baseline liver function tests (risk of hepatotoxicity, though generally reversible) 11
• Cardiovascular assessment (blood pressure, heart rate)
• Renal function assessment

During Treatment:

• Blood pressure and heart rate - monitor for hypotension and bradycardia, especially during titration 10
• Liver function tests - periodic monitoring given hepatotoxicity risk 2, 11
• Sedation level - most common adverse effect (62% of patients) 7
• Spasticity assessment using Modified Ashworth Scale at baseline and follow-up 7
• Muscle strength testing - tizanidine preserves strength unlike some alternatives 7

Food Effects and Administration

Food has complex effects on tizanidine pharmacokinetics 1. Switching between fed and fasted states can result in:

• Increased adverse events
• Delayed or more rapid onset of activity

Recommendation: Administer consistently either with or without food to maintain stable plasma levels 1.

Common Adverse Effects

Most frequent side effects 10, 7:

• Somnolence/drowsiness (62%)
• Dry mouth (common)
• Dizziness (32%)
• Ataxia or lethargy (dose-dependent)
• Hypotension and bradycardia

These effects are generally dose-dependent and manageable with slower titration 10.

Discontinuation Protocol

Never stop tizanidine abruptly in patients on long-term therapy 10. Withdrawal can cause:

• Rebound tachycardia
• Hypertension
• Hypertonia (increased muscle tone)

Taper slowly over several days to weeks when discontinuing 10.

Practical Advantages Over Alternatives

Compared to baclofen and diazepam, tizanidine offers 3, 5:

• Less subjective muscle weakness (critical for functional mobility)
• Better global tolerability (44-100% rated good-to-excellent vs 38-90% for baclofen, 20-54% for diazepam)
• Preserved muscle strength on objective testing 7
• Fewer cardiovascular effects than clonidine (its parent compound) 10

The 2021 SPAQI perioperative guidelines note emerging data showing tizanidine benefits including improved postoperative pain control, decreased opioid consumption, and hemodynamic stability 10.

Key Clinical Pearls

• High interpatient variability in plasma concentrations necessitates individualized dose titration 12
• Short duration of action (3-6 hours) makes it ideal for targeting specific daily activities when spasticity relief is most needed 1
• Maximum effect occurs within 1 week of reaching therapeutic dose 4
• Benefit maintained for at least 1 week after discontinuation 4
• Consider combination therapy with baclofen for improved spasticity control while managing dose-dependent adverse effects 5